Index
1 Market Overview of Oral Antidiabetic (OAD) Treatment
1.1 Oral Antidiabetic (OAD) Treatment Market Overview
1.1.1 Oral Antidiabetic (OAD) Treatment Product Scope
1.1.2 Oral Antidiabetic (OAD) Treatment Market Status and Outlook
1.2 Global Oral Antidiabetic (OAD) Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Oral Antidiabetic (OAD) Treatment Market Size by Region (2018-2029)
1.4 Global Oral Antidiabetic (OAD) Treatment Historic Market Size by Region (2018-2023)
1.5 Global Oral Antidiabetic (OAD) Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Oral Antidiabetic (OAD) Treatment Market Size (2018-2029)
1.6.1 North America Oral Antidiabetic (OAD) Treatment Market Size (2018-2029)
1.6.2 Europe Oral Antidiabetic (OAD) Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific Oral Antidiabetic (OAD) Treatment Market Size (2018-2029)
1.6.4 Latin America Oral Antidiabetic (OAD) Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa Oral Antidiabetic (OAD) Treatment Market Size (2018-2029)
2 Oral Antidiabetic (OAD) Treatment Market by Type
2.1 Introduction
2.1.1 Sulphonylureas
2.1.2 Biguanides
2.1.3 Intestinal α-Glucosidase Inhibitors
2.1.4 Others
2.2 Global Oral Antidiabetic (OAD) Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Oral Antidiabetic (OAD) Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global Oral Antidiabetic (OAD) Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Oral Antidiabetic (OAD) Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Oral Antidiabetic (OAD) Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Oral Antidiabetic (OAD) Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Oral Antidiabetic (OAD) Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Oral Antidiabetic (OAD) Treatment Revenue Breakdown by Type (2018-2029)
3 Oral Antidiabetic (OAD) Treatment Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Clinics
3.1.3 Diabetics Treatment Centres
3.1.4 Others
3.2 Global Oral Antidiabetic (OAD) Treatment Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Oral Antidiabetic (OAD) Treatment Historic Market Size by Application (2018-2023)
3.2.2 Global Oral Antidiabetic (OAD) Treatment Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Oral Antidiabetic (OAD) Treatment Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Oral Antidiabetic (OAD) Treatment Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Oral Antidiabetic (OAD) Treatment Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Oral Antidiabetic (OAD) Treatment Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Oral Antidiabetic (OAD) Treatment Revenue Breakdown by Application (2018-2029)
4 Oral Antidiabetic (OAD) Treatment Competition Analysis by Players
4.1 Global Oral Antidiabetic (OAD) Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Oral Antidiabetic (OAD) Treatment as of 2022)
4.3 Date of Key Players Enter into Oral Antidiabetic (OAD) Treatment Market
4.4 Global Top Players Oral Antidiabetic (OAD) Treatment Headquarters and Area Served
4.5 Key Players Oral Antidiabetic (OAD) Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Oral Antidiabetic (OAD) Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Oral Antidiabetic (OAD) Treatment Products, Services and Solutions
5.1.4 Pfizer Oral Antidiabetic (OAD) Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 Pfizer Recent Developments
5.2 Eli Lilly
5.2.1 Eli Lilly Profile
5.2.2 Eli Lilly Main Business
5.2.3 Eli Lilly Oral Antidiabetic (OAD) Treatment Products, Services and Solutions
5.2.4 Eli Lilly Oral Antidiabetic (OAD) Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 Eli Lilly Recent Developments
5.3 Merck
5.3.1 Merck Profile
5.3.2 Merck Main Business
5.3.3 Merck Oral Antidiabetic (OAD) Treatment Products, Services and Solutions
5.3.4 Merck Oral Antidiabetic (OAD) Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 Sanofi Recent Developments
5.4 Sanofi
5.4.1 Sanofi Profile
5.4.2 Sanofi Main Business
5.4.3 Sanofi Oral Antidiabetic (OAD) Treatment Products, Services and Solutions
5.4.4 Sanofi Oral Antidiabetic (OAD) Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 Sanofi Recent Developments
5.5 AstraZeneca
5.5.1 AstraZeneca Profile
5.5.2 AstraZeneca Main Business
5.5.3 AstraZeneca Oral Antidiabetic (OAD) Treatment Products, Services and Solutions
5.5.4 AstraZeneca Oral Antidiabetic (OAD) Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 AstraZeneca Recent Developments
5.6 Glenmark
5.6.1 Glenmark Profile
5.6.2 Glenmark Main Business
5.6.3 Glenmark Oral Antidiabetic (OAD) Treatment Products, Services and Solutions
5.6.4 Glenmark Oral Antidiabetic (OAD) Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 Glenmark Recent Developments
5.7 Novartis
5.7.1 Novartis Profile
5.7.2 Novartis Main Business
5.7.3 Novartis Oral Antidiabetic (OAD) Treatment Products, Services and Solutions
5.7.4 Novartis Oral Antidiabetic (OAD) Treatment Revenue (US$ Million) & (2018-2023)
5.7.5 Novartis Recent Developments
5.8 Boehringer Ingelheim
5.8.1 Boehringer Ingelheim Profile
5.8.2 Boehringer Ingelheim Main Business
5.8.3 Boehringer Ingelheim Oral Antidiabetic (OAD) Treatment Products, Services and Solutions
5.8.4 Boehringer Ingelheim Oral Antidiabetic (OAD) Treatment Revenue (US$ Million) & (2018-2023)
5.8.5 Boehringer Ingelheim Recent Developments
5.9 Novo Nordisk
5.9.1 Novo Nordisk Profile
5.9.2 Novo Nordisk Main Business
5.9.3 Novo Nordisk Oral Antidiabetic (OAD) Treatment Products, Services and Solutions
5.9.4 Novo Nordisk Oral Antidiabetic (OAD) Treatment Revenue (US$ Million) & (2018-2023)
5.9.5 Novo Nordisk Recent Developments
5.10 Mannkind
5.10.1 Mannkind Profile
5.10.2 Mannkind Main Business
5.10.3 Mannkind Oral Antidiabetic (OAD) Treatment Products, Services and Solutions
5.10.4 Mannkind Oral Antidiabetic (OAD) Treatment Revenue (US$ Million) & (2018-2023)
5.10.5 Mannkind Recent Developments
6 North America
6.1 North America Oral Antidiabetic (OAD) Treatment Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Oral Antidiabetic (OAD) Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Oral Antidiabetic (OAD) Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Oral Antidiabetic (OAD) Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Oral Antidiabetic (OAD) Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Oral Antidiabetic (OAD) Treatment Market Dynamics
11.1 Oral Antidiabetic (OAD) Treatment Industry Trends
11.2 Oral Antidiabetic (OAD) Treatment Market Drivers
11.3 Oral Antidiabetic (OAD) Treatment Market Challenges
11.4 Oral Antidiabetic (OAD) Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List